Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help ...
Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors ...
- The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines - Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed ...
First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to ...
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information". a) Acquisition-related expenses include ...
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
The table above provides additional details regarding the specified items described on tables titled "Non-GAAP Reconciliation of Financial Information." a) Acquisition-related expenses include ...
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Reflects the net tax benefit associated with the ...
2021 Taxes on Earnings includes the recognition of approximately $40 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately $45 ...
ABBOTT PARK, Ill., Sept. 28, 2016 — Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose ...
The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information." Restructuring and cost reduction initiative ...
Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results